Moreover, the risk of adverse outcomes increased with an AST/ALT ratio of <2.65, and incidence of adverse 28-day and 90-day outcomes significantly increased with an AST/ALT ratio ranged from 1.38 to 2.65 in patients with cirrhosis. This evidence concerns the gene GPT and Cirrhosis.